1. RECIST 1.1-Update and clarification: from the RECIST committee;Schwartz;Eur J Cancer,2016
2. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009
3. Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense;Dodd;J Clin Oncol,2008
4. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry;Office of the Commissioner;US Food Drug Adm,2019
5. Committee for medicinal products for human use (CHMP) - guideline on the evaluation of anticancer medicinal products in man;European Medicines Agency;Eur Med Agency,2017